175 lines
84 KiB
Text
175 lines
84 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548726">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548726/?report=reader">
|
|
<meta name="ncbi_pagename" content="Metformin - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Metformin - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Metaxalone/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Methadone/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Metformin">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2020/01/21">
|
|
<meta name="citation_pmid" content="31644035">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548726/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Metformin">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2020/01/21">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548726/">
|
|
<meta name="description" content="Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas, thiazolidinediones, incretin-based drugs, sodium glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin has not been linked to serum enzyme elevations during therapy and is an exceeding rare cause of idiosyncratic clinically apparent acute liver injury.">
|
|
<meta name="og:title" content="Metformin">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas, thiazolidinediones, incretin-based drugs, sodium glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin has not been linked to serum enzyme elevations during therapy and is an exceeding rare cause of idiosyncratic clinically apparent acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548726/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Metformin/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548726/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DBA437D7D4CC100000000010A00DA.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548726/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Metaxalone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Metformin</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Methadone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548726/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548726/&text=Metformin"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548726/?report=classic">Switch to classic view</a><a href="/books/NBK548726/pdf/Bookshelf_NBK548726.pdf">PDF (150K)</a><a href="/books/NBK548726/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548726%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DBA437D7D4CC100000000010A00DA.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548726_"><span class="title" itemprop="name">Metformin</span></h1><p class="fm-aai"><a href="#_NBK548726_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Metformin.OVERVIEW"><h2 id="_Metformin_OVERVIEW_">OVERVIEW</h2><div id="Metformin.Introduction"><h3>Introduction</h3><p>Metformin is a first line agent for the treatment of type 2 diabetes that can be used alone or in combination with sulfonylureas, thiazolidinediones, incretin-based drugs, sodium glucose cotransporter-2 inhibitors, or other hypoglycemic agents. Metformin has not been linked to serum enzyme elevations during therapy and is an exceeding rare cause of idiosyncratic clinically apparent acute liver injury.</p></div><div id="Metformin.Background"><h3>Background</h3><p>Metformin (met for' min) is a biguanine and acts as an insulin sensitizing agent, probably through activation of adenosine monophosphate dependent (AMP) kinase in liver and muscle tissue. Metformin is often associated with weight loss making it a preferred, first line agent for management of overweight patients with type 2 diabetes. Initial concerns about the possibility that metformin (like the related biguanine phenformin) could induce lactic acidosis have been largely resolved, although the agent is contraindicated in patients with renal dysfunction because of this reason and should be used with caution in patients with significant liver disease. Metformin was approved for use in the United States in 1995 and is currently one of the most commonly used drugs for the therapy of diabetes, with more than 30 million prescriptions filled in the United States yearly. Metformin is available in many generic forms in tablets of 500, 850 or 1000 mg, the recommended regimen being to start with 500 or 850 mg once daily and increase based upon tolerance to 1000 to 2550 mg daily taken in two divided doses. Commercial formulations include Glucophage, Glumetza, Fortamet and Riomet. Metformin is also available in extended release formulations and in combinations with sulfonylureas such as glipizide (Metaglip) or glyburide (Glucovance), DDP-4 inhibitors such as alogliptin (Kazano), linagliptin (Jentadueto), saxagliptin (Kombiglyze) and sitagliptin (Janumet), as well as thiazolidinediones such as pioglitazone (Actoplus) and rosiglitazone (Avandamet). Metformin is generally well tolerated but side effects can include diarrhea, gastrointestinal upset, abdominal pain, nausea, metallic taste, weakness, headache, dizziness and rash. Rare but potentially severe adverse events include lactic acidosis, hypoglycemia, dehydration and hypersensitivity reactions.</p></div><div id="Metformin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Minor enzyme elevations have been reported to occur during metformin therapy in less than 1% of patients. Indeed, metformin may actually lower elevated aminotransferase levels in patients with fatty liver disease. Clinically apparent liver injury from metformin is very rare, fewer than a dozen cases having been described in the literature despite widespread use of this agent for several decades. The liver injury usually appears after 1 to 8 weeks, typically with symptoms of weakness and fatigue followed by jaundice. Various combinations of hepatocellular and cholestatic injury have been described, and many have been mixed. Allergic manifestations are not typical but rash, fever and eosinophilia have been described. Autoantibody formation is also not typical. Because this agent is usually given in combination with other hypoglycemic agents, many of which also cause liver injury, it can be difficult to establish whether the injury is due to metformin or another agent. The timing of injury is perhaps most characteristic, the injury arising soon after the agent is started and not during long term therapy. Recovery is usually rapid after metformin is stopped.</p><p>Likelihood score: B (rare but well documented cause of clinically apparent liver injury).</p></div><div id="Metformin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of liver injury due to metformin is unknown. Metformin may actually be beneficial for some forms of liver disease, such as nonalcoholic steatohepatitis and need not be avoided in patients with mild, preexisting serum enzyme abnormalities. Acute liver injury from metformin may have a metabolic basis, arising after weeks to months of therapy. Rechallenge can lead to recurrence, but also requires weeks to months of therapy before injury reappears.</p></div><div id="Metformin.Outcome_and_Management"><h3>Outcome and Management</h3><p>The liver injury from metformin usually resolves rapidly once the agent is stopped. Chronic injury has not been described. No convincing cases of fulminant hepatic failure from metformin have been reported. In cases in which multiple hypoglycemic agents were being used when the liver injury appears, rechallenge with the agent least likely associated with the injury is appropriate. There is no cross reactivity in hepatotoxicity with other antidiabetic medications.</p><p>Drug Class: <a href="/books/n/livertox/Antidiabetic/?report=reader">Antidiabetic Agents</a></p></div></div><div id="Metformin.CASE_REPORTS"><h2 id="_Metformin_CASE_REPORTS_">CASE REPORTS</h2><div id="Metformin.Case_1_Acute_hepatitis_due_to"><h3>Case 1. Acute hepatitis due to metformin.(<a class="bibr" href="#Metformin.REF.1" rid="Metformin.REF.1">1</a>)</h3><p>A 67 year old woman with diabetes was started on metformin (500 mg twice daily) and developed fatigue, weakness and jaundice five weeks later. She had no history of liver disease or risk factors for viral hepatitis and did not drink alcohol. She had coronary artery disease and medications taken chronically included aspirin, isosorbide mononitrate, diltiazem and acarbose. On admission, 6 weeks after starting metformin, she had a total bilirubin of 4.8 mg/dL (Table). Tests for hepatitis A, B and C were negative. She had antinuclear antibodies (1:320). An abdominal ultrasound and CT scan were normal. Liver biopsy showed acute inflammation. Metformin and acarbose were withdrawn and gliclazide started. The jaundice slowly resolved over the next three months, but metformin was subsequently restarted, and jaundice reappeared 3 months later. Metformin was again withdrawn and her liver injury improved slowly.</p><div id="Metformin.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetforminTc"><a href="/books/NBK548726/table/Metformin.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetforminTc" rid-ob="figobMetforminTc"><img class="small-thumb" src="/books/NBK548726/table/Metformin.Tc/?report=thumb" src-large="/books/NBK548726/table/Metformin.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metformin.Tc"><a href="/books/NBK548726/table/Metformin.Tc/?report=objectonly" target="object" rid-ob="figobMetforminTc">Table</a></h4></div></div></div><div id="Metformin.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetforminTd"><a href="/books/NBK548726/table/Metformin.Td/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetforminTd" rid-ob="figobMetforminTd"><img class="small-thumb" src="/books/NBK548726/table/Metformin.Td/?report=thumb" src-large="/books/NBK548726/table/Metformin.Td/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metformin.Td"><a href="/books/NBK548726/table/Metformin.Td/?report=objectonly" target="object" rid-ob="figobMetforminTd">Table</a></h4></div></div></div><div id="Metformin.Comment"><h4>Comment</h4><p>This patient developed an acute hepatitis-like illness with mild jaundice after 5 weeks of therapy with metformin which was somewhat slow to resolve. Upon rechallenge, there was a recurrence of the liver injury, but only after metformin had been given for several months. Nevertheless, the pattern and subsequent course of the liver injury was similar to the original episode making it likely that metformin was the cause of the injury. While most causes of liver injury were excluded (hepatitis A, B and C, cholecystitis), the presence of a strongly positive ANA raises the possibility that the patient had autoimmune hepatitis with an acute, fluctuating onset and course. The liver biopsy apparently did not suggest autoimmune hepatitis, but this possibility can be excluded only by further follow up. In assessing hepatotoxicity from commonly used medications such as metformin, the possibility of an unusual presentation of a common liver disease must always be considered.</p></div></div><div id="Metformin.Case_2_Acute_hepatitislike_inj"><h3>Case 2. Acute hepatitis-like injury due to metformin.(<a class="bibr" href="#Metformin.REF.2" rid="Metformin.REF.2">2</a>)</h3><p>A 73 year old Japanese woman with poorly controlled diabetes, despite therapy with a sulfonylurea and pioglitazone, was started on metformin (500 mg twice daily) and developed fatigue, weakness and jaundice 3 weeks later. She was known to have had normal liver tests before starting metformin. On admission, laboratory testing showed a total bilirubin of 6.5 mg/dL and a hepatocellular pattern of serum enzyme elevations (Table). All oral antidiabetic agents were stopped and she was managed on insulin. Tests for hepatitis B and C infection were negative as were autoantibodies. Ultrasound, CT and ERCP were unremarkable. Her serum enzymes improved rapidly once metformin was stopped and were normal 7 weeks later.</p><div id="Metformin.Key_Points_1"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetforminTe"><a href="/books/NBK548726/table/Metformin.Te/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetforminTe" rid-ob="figobMetforminTe"><img class="small-thumb" src="/books/NBK548726/table/Metformin.Te/?report=thumb" src-large="/books/NBK548726/table/Metformin.Te/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metformin.Te"><a href="/books/NBK548726/table/Metformin.Te/?report=objectonly" target="object" rid-ob="figobMetforminTe">Table</a></h4></div></div></div><div id="Metformin.Laboratory_Values_1"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetforminTf"><a href="/books/NBK548726/table/Metformin.Tf/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetforminTf" rid-ob="figobMetforminTf"><img class="small-thumb" src="/books/NBK548726/table/Metformin.Tf/?report=thumb" src-large="/books/NBK548726/table/Metformin.Tf/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metformin.Tf"><a href="/books/NBK548726/table/Metformin.Tf/?report=objectonly" target="object" rid-ob="figobMetforminTf">Table</a></h4></div></div></div><div id="Metformin.Comment_1"><h4>Comment</h4><p>The patient developed an acute hepatitis-like illness with mild jaundice 3 weeks after metformin was added to a chronic regimen of a metiglinide analogue and thiazolidinedione for poorly controlled diabetes. Symptoms resolved within 2 weeks and all liver tests were normal 7 weeks after stopping the medications. No other cause for acute hepatitis was identified. Both nateglinide and pioglitazone have been reported to cause liver injury, but the timing of onset of the hepatitis most closely implicates metformin. Rechallenge with the other antidiabetic medications would have been appropriate.</p></div></div></div><div id="Metformin.PRODUCT_INFORMATION"><h2 id="_Metformin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Metformin – Generic, Fortamet®, Glucophage®, Riomet®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antidiabetic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Metformin" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">
|
|
<b>COMPLETE LABELING</b>
|
|
</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Metformin.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Metformin_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMetforminTg"><a href="/books/NBK548726/table/Metformin.Tg/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figMetforminTg" rid-ob="figobMetforminTg"><img class="small-thumb" src="/books/NBK548726/table/Metformin.Tg/?report=thumb" src-large="/books/NBK548726/table/Metformin.Tg/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Metformin.Tg"><a href="/books/NBK548726/table/Metformin.Tg/?report=objectonly" target="object" rid-ob="figobMetforminTg">Table</a></h4></div></div></div><div id="Metformin.CITED_REFERENCES"><h2 id="_Metformin_CITED_REFERENCES_">CITED REFERENCES</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="Metformin.REF.1">Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>2004;<span class="ref-vol">140</span>:W25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14996697" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14996697</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="Metformin.REF.2">Kutoh E. Possible metformin-induced hepatotoxicity. <span><span class="ref-journal">Am J Geriatr Pharmacother. </span>2005;<span class="ref-vol">3</span>:270–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16503324" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16503324</span></a>]</div></dd></dl></dl></div><div id="Metformin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Metformin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 21 January 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Metformin.REF.zimmerman.1999">Zimmerman HJ. Oral hypoglycemic agents and other diabetes therapy. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 578.<div><i>(Expert review of biguanides and liver injury published in 1999 which mentions that metformin, despite use for several years, had not been implicated in causing hepatic injury).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.de_marzio.2013">De Marzio DH, Navarro VJ. Biguanides. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 531.<div><i>(Review of hepatotoxicity of drugs for diabetes metions that metformin can cause either a cholestatic or hepatocellular pattern of liver injury, with latency of 1 to 8 weeks, and which resolve rapidly when metformin is stopped, no fatal cases having been described).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.powers.2018">Powers AC, D'Alessio D. Therapy of diabetes. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In, Brunton LL, Chabner BAHillal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 870-83.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.cubukcu.1991.447">Cubukcu A, Yilmaz MT, Satman I, Buyukdevrim AS. Metformin kullanimina bagli bir akut hepatiti vakasi (metformin-induced hepatitis). <span><span class="ref-journal">Tip Fak Mecm. </span>1991;<span class="ref-vol">54</span>:447–52.</span> [Turkish]. [Not in PubMed]<div>
|
|
<i>(57 year old woman developed jaundice 4 weeks after starting metformin [bilirubin 4.3 mg/dL, ALT 453, Alk P ~2x ULN], resolving within 4 weeks of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.bailey.1996.574">Bailey CJ, Turner RC. Metformin. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">334</span>:574–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8569826" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8569826</span></a>]<div>
|
|
<i>(Clinical review of pharmacokinetics, mechanism of action, efficacy and safety of metformin as therapy of type 2 diabetes; no mention of hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.babich.1998.490">Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. <span><span class="ref-journal">Am J Med. </span>1998;<span class="ref-vol">104</span>:490–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9626034" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9626034</span></a>]<div>
|
|
<i>(52 year old woman developed fatigue after 3 weeks of metformin therapy, followed by jaundice [bilirubin 14.4 mg/dL, ALT 651 U/L, Alk P 500 U/L], with resolution within a month of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.lin.1998.1860">Lin KD, Lin JD, Juang JH. Metformin-induced hemolysis with jaundice. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">339</span>:1860–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9867572" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9867572</span></a>]<div>
|
|
<i>(46 year old man became jaundiced within 2 weeks of starting metformin, with normal ALT and evidence of hemolysis; jaundice reappeared with rechallenge).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.swislocki.1998.677">Swislocki AL, Noth R. Case report. Pseudohepatotoxicity of metformin. <span><span class="ref-journal">Diabetes Care. </span>1998;<span class="ref-vol">21</span>:677–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9571371" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9571371</span></a>]<div>
|
|
<i>(75 year old man with Paget's disease and diabetes developed elevations in serum ALT [33 to 413 U/L] and AST [36 to 322 U/L] and worsening Alk P [470 to 684 U/L], without symptoms or jaundice after 2 months of metformin therapy; rechallenge for 1 month was not followed by recurrence; authors concluded that this represented "pseudohepatotoxicity").</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.crespo_valad_s.1999">Crespo Valadés E, Ortega Gómez A, Alvarado Izquierdo MI, Magro Ledesma D. [Hepatotoxic reaction associated with metformin and chlorpropamide treatment] Rev Clin Esp 1999; 199: 118-9. Spanish. PMID: 10216414. [<a href="https://pubmed.ncbi.nlm.nih.gov/10216414" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10216414</span></a>]<div><i>(68 year old mother developed an acute immunoallergic reaction 2 days after starting metformin with fever, eosinophilia, rash and lymphadenopathy accompanied by a mild cholestatic hepatitis [bilirubin 2.2 mg/dL, ALT 327 U/L, Alk P 2553 U/L], rapidly resolving upon stopping therapy).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.chaudhry.2001.16">Chaudhry MU, Simmons DL. Case of the month. Hepatic and renal failure in a patient taking troglitazone and metformin. <span><span class="ref-journal">J Ark Med Soc. </span>2001;<span class="ref-vol">98</span>:16–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11452755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11452755</span></a>]<div>
|
|
<i>(54 year old man developed jaundice after 5 years of metformin and 2 years of troglitazone after episode of bloody diarrhea and hypotension [bilirubin 17 mg/dL, ALT 574 U/L, Alk P 125 U/L], resolving after stopping oral agents and stabilization of heart disease).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.desilets.2001.2257">Desilets DJ, Shorr AF, Moran KA, Holtzmuller KC. Cholestatic jaundice associated with the use of metformin. <span><span class="ref-journal">Am J Gastroenterol. </span>2001;<span class="ref-vol">96</span>:2257–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11467664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11467664</span></a>]<div>
|
|
<i>(64 year old man developed fatigue and jaundice 2 weeks after starting metformin [bilirubin 21.3 mg/dL, ALT 289 U/L, Alk P 994 U/L], resolving within 3 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.lebovitz.2002.815">Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. <span><span class="ref-journal">Diabetes Care. </span>2002;<span class="ref-vol">25</span>:815–21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11978674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11978674</span></a>]<div>
|
|
<i>(Analysis of more than 6000 patients in industry sponsored clinical trials found ALT levels >3 times ULN in 1.9% of troglitazone, 0.32% of rosiglitazone, 0.26% of pioglitazone, 0.40% of sulfonylurea and metformin, vs 0.17% of placebo treated patients; no mention of severe liver toxicity or jaundice).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.nammour.2003.307">Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. <span><span class="ref-journal">Endocr Pract. </span>2003;<span class="ref-vol">9</span>:307–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14561576" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14561576</span></a>]<div>
|
|
<i>(68 year old man developed severe jaundice 4 weeks after starting metformin [bilirubin 15.7 mg/dL, ALT 109 U/L, Alk P 383 U/L], biopsy showed severe cholestasis, slow recovery and Alk P still elevated 3 months later).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.deutsch.2004.w25">Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>2004;<span class="ref-vol">140</span>:W25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14996697" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14996697</span></a>]<div>
|
|
<i>(67 year old woman developed jaundice 5 weeks after starting metformin [bilirubin 4.8 mg/dL; ALT 905 U/L; Alk P 121 U/L], resolving within 2 months of stopping and recurring 3 months after restarting: Case 1).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.barquero_romero.2005">Barquero Romero J, Pérez Miranda M. [Metformin-induced cholestatic hepatitis] Gastroenterol Hepatol 2005; 28: 257-8. Spanish. PMID: 15811270. [<a href="https://pubmed.ncbi.nlm.nih.gov/15811270" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15811270</span></a>]<div><i>(80 year old woman developed jaundice ~10 weeks after starting metformin [bilirubin 5.3 mg/dL, ALT 174 U/L, Alk P 199 U/L], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.kutoh.2005.270">Kutoh E. Possible metformin-induced hepatotoxicity. <span><span class="ref-journal">Am J Geriatr Pharmacother. </span>2005;<span class="ref-vol">3</span>:270–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16503324" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16503324</span></a>]<div>
|
|
<i>(73 year old woman developed jaundice 3 weeks after addition of metformin to chronic therapy with nateglinide and pioglitazone [bilirubin 6.5 mg/dL, ALT 772 U/L, Alk P 635 U/L], resolving within 7 weeks of stopping: Case 2).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
|
<i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, no single agent case was attributed to metformin).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.de_la_poza_g_mez.2008">de la Poza Gómez G, Rivero Fernández M, Vázquez Romero M, Angueira Lapeña T, Arranz de la Mata G, Boixeda de Miquel D. [Constitutional syndrome associated to metformin induced hepatotoxicity]. Gastroenterol Hepatol 2008; 31: 643-5. Spanish. PMID: 19174081. [<a href="https://pubmed.ncbi.nlm.nih.gov/19174081" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19174081</span></a>]<div><i>(83 year old man developed fatigue, weakness and weight loss several weeks after starting metformin [bilirubin 2.3 mg/dL, ALT 740 U/L, Alk P 586 U/L]; symptoms resolved within 2 weeks and liver tests fell to normal within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.seidowsky.2009.2191">Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. <span><span class="ref-journal">Crit Care Med. </span>2009;<span class="ref-vol">37</span>:2191–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19487945" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19487945</span></a>]<div>
|
|
<i>(Among 42 patients with voluntary or inadvertent metformin overdose, most had lactic acidosis, 50% circulatory shock, 74% renal failure, 33% died; factors correlating with survival were lactate levels, pH, creatinine and prothrombin time).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.oliveragonz_lez.2010">Olivera-González S, de Escalante-Yangüela B, Velilla-Soriano C, Amores-Arriaga B, Martín-Fortea P, Navarro-Aguilar ME. [Metformin-associated hepatotoxicity.]. Med Intensiva 2010; 34: 483-7. Spanish. PMID: 20045581. [<a href="https://pubmed.ncbi.nlm.nih.gov/20045581" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20045581</span></a>]<div><i>(73 year old woman with diabetes and heart disease developed weakness and abdominal pain 2 weeks after starting metformin [bilirubin 1.4 mg/dL, ALT 1294 U/L, Alk P 95 U/L, LDH 4957 U/L, lactate 6.9 mmol/L, INR 7.4] resolving within 2 weeks of stopping metformin).</i></div></div></li><li><div class="bk_ref" id="Metformin.REF.cone.2010.1655">Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. <span><span class="ref-journal">Ann Pharmacother. </span>2010;<span class="ref-vol">44</span>:1655–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20647417" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20647417</span></a>]<div>
|
|
<i>(61 year old man with diabetes and fatty liver developed jaundice within 2 weeks of starting metformin [bilirubin 1.8 mg/dL, ALT 571 U/L, Alk P 143 U/L], resolving within 2 months of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div>
|
|
<i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 [11%] were attributed to drug induced liver injury, of which 4 were due to troglitazone but none to other antidiabetic medications).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.lavine.2011.1659">Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. <span><span class="ref-journal">JAMA. </span>2011;<span class="ref-vol">305</span>:1659–68.</span> [<a href="/pmc/articles/PMC3110082/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3110082</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21521847" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21521847</span></a>]<div>
|
|
<i>(Randomized controlled trial of metformin vs vitamin E vs placebo in 173 children with nonalcoholic fatty liver disease; serum aminotransferase levels fell in all three groups and no patient developed jaundice or evidence of hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF26">Drugs for type 2 diabetes. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2011;<span class="ref-vol">9</span>:47–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21778966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21778966</span></a>]<div>
|
|
<i>(Concise review of the role of antidiabetic medications in management of type 2 diabetes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.arroyo.2011.749653">Arroyo D, Melero R, Panizo N, Goicoechea M, Rodríguez-Benítez P, Vinuesa SG, Verde E, et al. Metformin-associated acute kidney injury and lactic acidosis. <span><span class="ref-journal">Int J Nephrol. </span>2011;<span class="ref-vol">2011</span>:749653. </span> [<a href="/pmc/articles/PMC3139902/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3139902</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21792389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21792389</span></a>]<div>
|
|
<i>(Between 2006 and 2010, 29 patients presented with lactic acidosis and acute renal injury on metformin [duration not given], 10 of whom had underlying liver disease, which appeared to be a risk factor).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.miralleslinares.2012.e21">Miralles-Linares F, Puerta-Fernandez S, Bernal-Lopez MR, Tinahones FJ, Andrade RJ, Gomez-Huelgas R. Metformin-induced hepatotoxicity. <span><span class="ref-journal">Diabetes Care. </span>2012;<span class="ref-vol">35</span>(3):e21. </span> [<a href="/pmc/articles/PMC3322705/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3322705</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22355024" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22355024</span></a>]<div>
|
|
<i>(61 year old man developed jaundice 6 weeks after starting metformin [bilirubin 2.9 mg/dL, ALT 861 U/L, Alk P 622 U/L], resolving within 4 weeks of stopping and recurring within 24 hours of restarting [bilirubin 4.8 mg/dL, ALT 764 U/L, Alk P 622 U/L], resolving again within 4 weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced lLiver injury in the General population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
|
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were due to metformin or other antidiabetic medications).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.zheng.2016.e315">Zheng L. Metformin as a rare cause of drug-induced liver injury, a case report and literature review. <span><span class="ref-journal">Am J Ther. </span>2016;<span class="ref-vol">23</span>(1):e315–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24263160" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24263160</span></a>]<div>
|
|
<i>(70 year old woman developed nausea and abdominal pain 5 weeks after starting metformin [bilirubin 2.2 mg/dL, ALT 1093 U/L, Alk P 176 U/L], resolving within 14 days of stopping).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.saadi.2013.703">Saadi T, Waterman M, Yassin H, Baruch Y. Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. <span><span class="ref-journal">Int J Gen Med. </span>2013;<span class="ref-vol">6</span>:703–6.</span> [<a href="/pmc/articles/PMC3751382/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3751382</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23983487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23983487</span></a>]<div>
|
|
<i>(78 year old man developed fatigue within a week of starting metformin, followed by jaundice [bilirubin 22.2 mg/dL, ALT 1050 U/L, Alk P 1001 U/L], resolving within 2 months of stopping; also received amoxicillin/clavulanate).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF32">Drugs for type 2 diabetes. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2014;<span class="ref-vol">12</span>(139):17–24.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24566424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24566424</span></a>]<div>
|
|
<i>(Concise recommendations on drugs for type 2 diabetes mentions that metformin is generally the preferred first line agent; side effects include metabllic taste, nausea, diarrhea, abdominal pain, and [in patients with impaired renal function] lactic acidosis; no mention of hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.hern_ndez.2014.231">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div>
|
|
<i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to metformin).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div>
|
|
<i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 4 were attributed to antidiabetic medications, including 2 to metformin, one to sitagliptin and one to glibenclamide).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF35">Metformin for prediabetes. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1507):141.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27805573" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27805573</span></a>]<div>
|
|
<i>(Concise discussion of use of long term metformin to prevent diabetes in patients with elevated fasting and postprandial plasma glucose, discusses common adverse events but does not mention ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF.thalha.2018.242">Thalha AM, Mahadeva S, Boon Tan AT, Mun KS. Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. <span><span class="ref-journal">JGH Open. </span>2018;<span class="ref-vol">2</span>:242–5.</span> [<a href="/pmc/articles/PMC6207028/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6207028</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30483596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30483596</span></a>]<div>
|
|
<i>(33 year old man with diabetes developed pruritus 1 week after starting the combination of metformin and saxagliptin [bilirubin 0.7 mg/dL, ALT 307 U/L, GGT 808 U/L], resolving within 2 months of stopping the combination agent and later tolerating, without worsening liver tests, the re-introduction of metformin suggesting that saxagliptin was the cause).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Metformin.REF37">Drugs for type 2 diabetes. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2019;<span class="ref-vol">61</span>(1584):169–78.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31770362" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31770362</span></a>]<div>
|
|
<i>(Concise recommendations on drugs for type 2 diabetes mentions that metformin is generally the drug of choice for initial treatment; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548726_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 21, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Metformin. [Updated 2020 Jan 21].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Metaxalone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Methadone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobMetforminTc"><div id="Metformin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548726/table/Metformin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metformin.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Metformin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Metformin.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metformin (500 mg twice daily)</td></tr><tr><th id="hd_b_Metformin.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Metformin.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=26)</td></tr><tr><th id="hd_b_Metformin.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Metformin.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (hospitalization for jaundice)</td></tr><tr><th id="hd_b_Metformin.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_Metformin.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td></tr><tr><th id="hd_b_Metformin.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Metformin.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complete within 2 months</td></tr><tr><th id="hd_b_Metformin.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Metformin.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Acarbose, diltiazem, aspirin, isosorbide mononitrate</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetforminTd"><div id="Metformin.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548726/table/Metformin.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metformin.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Metformin.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Metformin.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Metformin.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT*<br />(U/L)</th><th id="hd_h_Metformin.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Metformin.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin*<br />(mg/dL)</th><th id="hd_h_Metformin.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">905</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">121</td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.8</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ANA: 1:320</td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 week</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">960</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.5</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1160</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1080</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 months</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">280</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">120</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1 hd_h_Metformin.Td_1_1_1_2 hd_h_Metformin.Td_1_1_1_3 hd_h_Metformin.Td_1_1_1_4 hd_h_Metformin.Td_1_1_1_5 hd_h_Metformin.Td_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:center;vertical-align:top;">Metformin restarted approximately 4 months later</td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">880</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 week</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1240</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.5</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ANA still present</td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1120</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.2</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 weeks</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">920</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.1</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">800</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.5</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 months</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">480</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 months</td><td headers="hd_h_Metformin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Td_1_1_1_1 hd_h_Metformin.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Metformin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><40</b>
|
|
</td><td headers="hd_h_Metformin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><130</b>
|
|
</td><td headers="hd_h_Metformin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Metformin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>* </dt><dd><div id="Metformin.TF.d.1"><p class="no_margin">Values of ALT and bilirubin were estimated from the figure and converted from times upper limit of normal to absolute values based upon normal values provided.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobMetforminTe"><div id="Metformin.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548726/table/Metformin.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metformin.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Metformin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Metformin.Te_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metformin (500 mg twice daily)</td></tr><tr><th id="hd_b_Metformin.Te_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Metformin.Te_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=21)</td></tr><tr><th id="hd_b_Metformin.Te_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Metformin.Te_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (hospitalization for jaundice)</td></tr><tr><th id="hd_b_Metformin.Te_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_Metformin.Te_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td></tr><tr><th id="hd_b_Metformin.Te_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Metformin.Te_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complete within 2 months</td></tr><tr><th id="hd_b_Metformin.Te_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Metformin.Te_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nateglinide and pioglitazone for 6 months</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetforminTf"><div id="Metformin.Tf" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548726/table/Metformin.Tf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metformin.Tf_lrgtbl__"><table><thead><tr><th id="hd_h_Metformin.Tf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Metformin.Tf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Metformin.Tf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT<br />(U/L)</th><th id="hd_h_Metformin.Tf_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Metformin.Tf_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin<br />(mg/dL)</th><th id="hd_h_Metformin.Tf_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">337</td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">772</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">635</td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.5</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">480</td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.2</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">101</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.6</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Symptoms resolved</td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">65</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.7</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">13</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Metformin.Tf_1_1_1_1 hd_h_Metformin.Tf_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Metformin.Tf_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><36</b>
|
|
</td><td headers="hd_h_Metformin.Tf_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><359</b>
|
|
</td><td headers="hd_h_Metformin.Tf_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Metformin.Tf_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobMetforminTg"><div id="Metformin.Tg" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548726/table/Metformin.Tg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Metformin.Tg_lrgtbl__"><table><tbody><tr><th id="hd_b_Metformin.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Metformin.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Metformin.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Metformin.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Metformin.Tg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metformin</td><td headers="hd_b_Metformin.Tg_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134977327" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">657-24-9</a>
|
|
</td><td headers="hd_b_Metformin.Tg_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C4-H11-N5</td><td headers="hd_b_Metformin.Tg_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134977327" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134977327" alt="image 134977327 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|